Celebrating the Faces of Hope -- Past, Present and Future


May 7, 2010

Penn Medicine Invitation to Cover

New $25 Million Abramson Family Gift Ensures Future of Lifesaving Cancer Research at Penn Medicine

PHILADELPHIA – A special event will be held Monday, May 10 to honor a new, $25 million gift from Madlyn and Leonard Abramson, celebrate five decades of progress in cancer research and treatment at Penn Medicine, and highlight the promise of future work to conquer the disease.To illustrate the tremendous achievements that are turning cancer patients into survivors every day, the event will include presentations from the physicians who treat cancer using the latest targeted drug therapies, precision radiation technology and minimally invasive surgical techniques. The new gift brings the Abramson family’s total philanthropic support of Penn Medicine – which previously led to the naming of the Abramson Cancer Center and the establishment of the Abramson Family Cancer Research Institute – to $125 million. They are the largest donors to Penn Medicine.

WHERE:               Museum of Archaeology and Anthropology

                               Rainey Auditorium
                               3260 South Street
                               Philadelphia, PA 19104

WHEN:

Monday, May 10, 2010
5:30 PM to 6:45 PM

WHO:

Interviews available with:

WHAT:

The new gift will support continued basic science and translational research progress in the Abramson Family Cancer Research Institute, which is among the nation’s preeminent incubators for drug discovery and development of new ways to diagnose patients and pair them with treatments that will be most effective. In the 12 years since the establishment of the Institute, the Abramson family’s generous gift has led to:

  • Recruitment of 20 of the world’s best scientists to Penn Medicine’s faculty.
  • Establishment of new research programs in cancer cell metabolism, cancer vaccines, cell-based immunotherapy, and the study of the DNA repair system involved in breast cancer and lymphoma
  • Genome-wide studies that have yielded new therapeutic targets for brain and kidney cancers.
  • Blood and imaging tests to more easily diagnose cancers including leukemia and the deadly brain cancer glioblastoma.
  • Enrollment of hundreds of patients in trials testing therapeutic vaccines for lymphoma, prostate and breast cancers, and new targeted drug therapies for melanoma.

“The advances in cancer research developed at Penn’s Abramson Cancer Center have led to new prevention, diagnosis, and treatment programs that are awe-inspiring,” says Arthur H. Rubenstein, MBBCh, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the School of Medicine. “By fostering the spirit of scientific inquiry, the Abramsons have enabled the most talented minds in the country to engage in the most advanced basic and translational research right here in Philadelphia.”

###

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $3.6 billion enterprise.

Penn’s School of Medicine is currently ranked #2 in U.S. News & World Report’ssurvey of research-oriented medical schools, and is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $367.2 million awarded in the 2008 fiscal year.

Penn Medicine’s patient care facilities include:

Additional patient care facilities and services include Penn Medicine at Rittenhouse, a Philadelphia campus offering inpatient rehabilitation and outpatient care in many specialties; as well as a primary care provider network; a faculty practice plan; home care and hospice services; and several multispecialty outpatient facilities across the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2009, Penn Medicine provided $733.5 million to benefit our community.